English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/27343
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Prevention of in vivo excitotoxicity by a family of trialkylglycines, a novel class of neuroprotectants

AuthorsMontoliu, Carmina; Humet, Marc; Canales, Juan José; Burda, Jozef; Planells-Cases, Rosa; Sánchez Baeza, Francisco J. ; Carbonell, Teresa; Pérez-Payá, Enrique ; Messeguer Peypoch, Ángel
Issue DateApr-2002
CitationJournal of Pharmacology and Experimental Therapeutics 301(1): 29-36 (2002)
AbstractExcitotoxicity has been implicated in the etiology of ischemic stroke and chronic neurodegenerative disorders. Hence, the development of novel neuroprotectant molecules that ameliorate excitotoxic brain damage is vigorously pursued. We used a neuroprotection-based cellular assay to screen a synthetic combinatorial library of N-alkylglycine trimers. Two compounds (6-1-2 and 6-1-10) that efficiently prevented excitotoxic neurodegeneration in vitro and in vivo were identified. Both molecules protected primary cultures of cerebellar neurons against glutamate-induced neuronal death with an efficiency equivalent to N-methyl-D-aspartate (NMDA) receptor antagonists. These trialkylglycines did not block appreciably the NMDA receptor channel, or attenuated glutamate-induced increase of Ca(2+), or affect the glutamate-nitric oxide-cGMP pathway. Intraperitoneal injection of both peptoids in mice attenuated > or = 80% ammonia-induced, NMDA receptor-mediated animal death. Furthermore, these two molecules reduced by > or = 50% the neurodegeneration in striatum in a rat model of cerebral ischemia. Neuroprotection against ischemia was associated with decreased activation of caspase-3, reflecting prevention of apoptotic neuronal death. Collectively, the results reported indicate that these trialkylglycines are new neuroprotectant leads with important in vivo activity against excitotoxicity, and that they act on a novel, yet-unrecognized cellular target. These lead compounds may become tolerated drugs for the treatment of acute and chronic neurodegenerative diseases with fewer side effects than NMDA receptor antagonists.
Description8 pages, 8 figures, 1 table.-- PMID: 11907154 [PubMed].
Publisher version (URL)http://dx.doi.org/10.1124/jpet.301.1.29
URIhttp://hdl.handle.net/10261/27343
DOI10.1124/jpet.301.1.29
ISSN0022-3565
E-ISSN1521-0103
Appears in Collections:(IQAC) Artículos
Files in This Item:
File Description SizeFormat 
Montoliu_Carmina_et_al.pdf442,65 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.